Lupin

2,068.40
-4.50
(-0.22%)
Market Cap
94,636.40 Cr
EPS
42.05
PE Ratio
28.82
Dividend Yield
0.58 %
Industry
Healthcare
52 Week High
2,402.90
52 Week Low
1,493.30
PB Ratio
5.50
Debt to Equity
0.28
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from31 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+54.84 %
+54.84 %
Hold
Hold+32.26 %
+32.26 %
Sell
Sell+12.90 %
+12.90 %

Company News

View All News
Caret
negative
Lupin Warns of Innovation Impact from US Drug Pricing ReductionToday
During a conference call, Lupin expressed concern that reducing drug prices in the United States would significantly impact innovation in the pharmaceutical industry. The company stated that the US market is responsible for funding the majority of innovation in the sector.
positive
Lupin Reports Strong Growth Expectations and Margin ImprovementsToday
Lupin announced that its EBITDA margins are in line with its peer group and are expected to continue improving as new adjacencies grow and contribute to profits. The company expects to grow over $250 million per quarter and aims for sustainable double-digit growth. Lupin targets growth of 20-30% ahead of the market, which is expected to grow at 6-8%.
positive
Lupin Ltd: FDA Approval for Rivaroxaban Tablets and Strong Q4 Results1 day ago
Lupin received USFDA approval for Rivaroxaban Tablets in 10 mg, 15 mg, and 20 mg strengths. Q4 revenue increased 12.2% YoY to ₹5,567.1 crore, with profit surging 121.1% to ₹794.86 crore. US sales reached $245 million, up from $209 million last year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,734.90
#1 4,17,508.30
35.39
#1 49,887.20
12.06
#1 9,648
13.77
47.70
6,279.50
1,64,975.40
79.75
8,184.00
0.89
1,600
64.53
62.83
1,499.90
1,21,319.90
23.01
26,520.70
14.17
4,155
30.28
49.42
3,266.80
1,10,502.40
59.35
10,785.70
11.59
1,656
13.54
52.85
2,572.70
1,05,616.00
51.74
10,615.60
19.57
1,942
-16.38
59.84
1,230.70
1,03,163.70
#1 18.22
28,905.40
12.36
5,578
21.14
64.04
2,068.40
#7 94,636.40
#5 28.82
#5 20,141.50
#1 19.94
#7 1,936
#1 112.49
52.76
902.70
91,034.00
20.07
19,831.50
13.82
3,831
29.92
56.61
1,201.20
70,677.70
20.05
29,559.20
17.55
3,169
-10.04
51.74
30,560.00
64,449.10
48.36
6,097.20
10.80
1,201
27.83
54.55

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
19.94 %
Net Income Growth
332.34 %
Cash Flow Change
92.30 %
ROE
277.31 %
ROCE
143.65 %
EBITDA Margin (Avg.)
75.22 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
5,619
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
4,346
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
1,273
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
22 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
393
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
89
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
896
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
114
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
782
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75
16.93

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
Total Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
Share Capital
90
90
90
90
91
91
91
91
91
91

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
46.92 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
21.46 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
25.41 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
5.10 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
1.10 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988
2,83,210

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 7.5 5 5 6 6.5 4 4 8 0.00
Dividend Yield (%) 0.00 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 2,107.70 2,063.00
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Feb 2025 2,134.25 2,169.40
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 2,151.95 2,166.05
02 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
02 Aug 2024 1,778.90 1,953.55
16 Jul 2024 DIVIDEND Dividend
8.00 /share
16 Jul 2024 1,655.25 1,832.10
14 Jul 2023 DIVIDEND Dividend
4.00 /share
14 Jul 2023 732.25 930.75
15 Jul 2022 DIVIDEND Dividend
4.00 /share
14 Jul 2022 683.30 643.20
28 Jul 2021 DIVIDEND Dividend
6.50 /share
27 Jul 2021 1,212.25 1,111.60

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication4 hours ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome22 hours ago
Announcement under Regulation 30 (LODR)-Investor Presentation1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Corporate Action-Board approves Dividend1 day ago
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association1 day ago
Appointment Of M/S. Makarand M. Joshi & Co. Company Secretaries As Secretarial Auditors Of The Company For A Term Of Five Consecutive Years.1 day ago
Announcement under Regulation 30 (LODR)-Change in Directorate1 day ago
Board Meeting Outcome for Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 20251 day ago
Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 20251 day ago
Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2025 And Recommend Final Dividend Of Rs. 12/- Per Equity Share I.E. 600 % Of The Face Value Of Rs. 2/ Each Fully Paid Up For The Financial Year Ended March 31 20251 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 02, 2025
Updates On Transfer Of Companys API R&D Division And Over-The-Counter Consumer Healthcare Business On Slump Sale Basis.Apr 30, 2025
Board Meeting Intimation for Considering And Taking On Record Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2025 And Recommend Dividend If Any.Apr 29, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
The Company Has Informed The Exchange About Court Order In The Matter Of A Patent Case.Apr 16, 2025
Rumour verification - Regulation 30(11)Apr 16, 2025
Clarification sought from Lupin LtdApr 16, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 02, 2025
Announcement under Regulation 30 (LODR)-RestructuringMar 31, 2025
Announcement under Regulation 30 (LODR)-RestructuringMar 31, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On March 31 2025.Mar 31, 2025
Closure of Trading WindowMar 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 21, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Incorporation Of A Wholly Owned Subsidiary.Mar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 18, 2025

Technical Indicators

RSI(14)
Neutral
53.31
ATR(14)
Less Volatile
69.25
STOCH(9,6)
Neutral
59.47
STOCH RSI(14)
Neutral
58.44
MACD(12,26)
Bullish
0.76
ADX(14)
Weak Trend
9.59
UO(9)
Bearish
52.25
ROC(12)
Uptrend And Accelerating
0.28
WillR(14)
Neutral
-31.79

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Chairperson NameM D Gupta